ArticlePathogens (Basel, Switzerland)2025
Seroprevalence of Dengue, Chikungunya, and Zika Viruses Among Febrile Patients in Dhaka, Bangladesh: A Hospital-Based Cross-Sectional Study.
Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serological and Immunological Markers in Dengue Fever: A Retrospective ELISA-Based Pilot Study from Trinidad and Tobago.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Dengue (DENV), Chikungunya (CHIKV), and Zika (ZIKV) are emerging arboviral threats in Bangladesh, transmitted by Aedes mosquitoes thriving in urban Dhaka. Overlapping symptoms complicate diagnosis, and Bangladesh-specific data on arboviral antibody reactivity are limited. In four hospitals of Dhaka, we conducted a cross-sectional study on 438 febrile patients aged ≥10 years, collecting samples between September and December 2023 to describe arboviral antibody reactivity and their distribution across selected demographic and environmental characteristics. Rapid diagnostic tests (RDTs) for DENV and CHIKV were performed, followed by enzyme-linked immunosorbent assay (ELISA) on RDT-reactive samples. Participants had a mean age of 30 years (±13.5); two-thirds were male, and most lived in crowded, low-income households. RDTs indicated DENV/CHIKV antibody reactivity in 40% of participants; 170 samples underwent ELISA, suggesting DENV IgG reactivity in 33.5% and IgM reactivity in 15.5%. CHIKV IgG reactivity (0.7%) was low and ZIKV IgG was reactive in 21% of total samples, and IgM was reactive in one (0.2%); most ZIKV IgG-reactive samples also showed DENV IgG reactivity, suggesting cross-reactivity. DENV IgG and IgM reactivity were associated with lower education, while ZIKV IgM reactivity was associated with older age. Awareness of Aedes mosquitoes was low, and environmental risk factors were common. This study provides cross-sectional data on serological reactivity against DENV, CHIKV, and ZIKV among febrile patients attending four hospitals of Dhaka, without aiming to establish etiologic causes of illness. ZIKV IgG antibody reactivity requires confirmatory testing to distinguish true infections from other arboviral cross-reactivity. Strengthened community-based surveys, better public awareness, and sustained vector control are critical for reducing arboviral disease risks in urbanizing settings like Dhaka, Bangladesh.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.